Kiora Pharmaceuticals, Inc. is registering 11,797,088 shares of Common Stock for resale by selling stockholders.
The registration covers (i) 438,471 shares issued in a Private Placement, (ii) 1,527,710 shares underlying pre-funded warrants, (iii) 7,864,726 shares underlying Tranche A-1 warrants, and (iv) 1,966,181 shares underlying Tranche A-2 warrants. The Company is not offering any shares for its own account and will receive no proceeds from resales; however, the Company would receive proceeds from any warrant cash exercises. The prospectus states that the registered securities represent approximately 72.7% of outstanding common stock as of May 14, 2026 after giving effect to the registered underlying shares. The resale may occur from time to time through public or private transactions as described in the Plan of Distribution.
Kiora Pharmaceuticals, Inc. is registering 11,797,088 shares of Common Stock for resale by selling stockholders.
The registration covers (i) 438,471 shares issued in a Private Placement, (ii) 1,527,710 shares underlying pre-funded warrants, (iii) 7,864,726 shares underlying Tranche A-1 warrants, and (iv) 1,966,181 shares underlying Tranche A-2 warrants. The Company is not offering any shares for its own account and will receive no proceeds from resales; however, the Company would receive proceeds from any warrant cash exercises. The prospectus states that the registered securities represent approximately 72.7% of outstanding common stock as of May 14, 2026 after giving effect to the registered underlying shares. The resale may occur from time to time through public or private transactions as described in the Plan of Distribution.
Kiora Pharmaceuticals, Inc. reports that Nantahala Capital Management, LLC and its principals, Wilmot B. Harkey and Daniel Mack, may be deemed beneficial owners of 438,469 shares of common stock as of March 31, 2026. The filing states those shares represent 9.99% of the outstanding common stock and that the 438,469 shares include shares issuable upon exercise of convertible securities within sixty days. The reporting persons disclose shared voting and dispositive power over the 438,469 shares. A fund advised by Nantahala, BLACKWELL PARTNERS LLC - SERIES A, is identified as having the right to receive dividends or sale proceeds on more than 5% of those shares.
Kiora Pharmaceuticals, Inc. reports that Nantahala Capital Management, LLC and its principals, Wilmot B. Harkey and Daniel Mack, may be deemed beneficial owners of 438,469 shares of common stock as of March 31, 2026. The filing states those shares represent 9.99% of the outstanding common stock and that the 438,469 shares include shares issuable upon exercise of convertible securities within sixty days. The reporting persons disclose shared voting and dispositive power over the 438,469 shares. A fund advised by Nantahala, BLACKWELL PARTNERS LLC - SERIES A, is identified as having the right to receive dividends or sale proceeds on more than 5% of those shares.
KIORA PHARMACEUTICALS, INC. filing: Alyeska Investment Group and related filers report 394,668 shares beneficially owned, representing 9.99% of Common Stock as of March 31, 2026. The position equals the maximum exercisable under a beneficial ownership limitation tied to warrants.
The filing states the Reporting Persons hold warrants exercisable for 596,854 shares, but the 9.99% limitation permits exercise of only 394,668 shares based on 3,950,628 shares outstanding per the Form 10-K dated March 25, 2026. Voting and investment control is exercised by Alyeska Investment Group, L.P.; Anand Parekh is named but disclaims beneficial ownership.
KIORA PHARMACEUTICALS, INC. filing: Alyeska Investment Group and related filers report 394,668 shares beneficially owned, representing 9.99% of Common Stock as of March 31, 2026. The position equals the maximum exercisable under a beneficial ownership limitation tied to warrants.
The filing states the Reporting Persons hold warrants exercisable for 596,854 shares, but the 9.99% limitation permits exercise of only 394,668 shares based on 3,950,628 shares outstanding per the Form 10-K dated March 25, 2026. Voting and investment control is exercised by Alyeska Investment Group, L.P.; Anand Parekh is named but disclaims beneficial ownership.
Kiora Pharmaceuticals reported that Nantahala Capital Partners LP amended its Schedule 13G to state beneficial ownership of 148,736 shares as of March 31, 2026. The filing notes those 148,736 shares include shares acquirable upon exercise of warrants within sixty days. The position represents 3.388% of the class, based on 4,431,940 shares outstanding as of the 10-Q filed May 8, 2026.
Kiora Pharmaceuticals reported that Nantahala Capital Partners LP amended its Schedule 13G to state beneficial ownership of 148,736 shares as of March 31, 2026. The filing notes those 148,736 shares include shares acquirable upon exercise of warrants within sixty days. The position represents 3.388% of the class, based on 4,431,940 shares outstanding as of the 10-Q filed May 8, 2026.
Kiora Pharmaceuticals reported first quarter 2026 results, highlighting clinical progress in its retinal disease pipeline and a modestly higher net loss. The company recorded a net loss of $2.4 million for the quarter, or $0.58 per basic and diluted share.
Kiora ended March 31, 2026 with $13.9 million in cash and short-term investments and subsequently raised an additional $5.0 million through a strategic equity financing. Management believes this supports an operational runway into late 2028, beyond anticipated data readouts from its KIO-301 ABACUS-2 and KIO-104 KLARITY Phase 2 trials.
Enrollment in ABACUS-2 for KIO-301 is roughly half complete, supported by strong patient demand and expanded trial sites, and prior ABACUS-1 data were published in Nature Medicine. KIO-104 continues in the KLARITY study, with a planned safety review expected to enable escalation to a higher dose cohort.
Kiora Pharmaceuticals reported first quarter 2026 results, highlighting clinical progress in its retinal disease pipeline and a modestly higher net loss. The company recorded a net loss of $2.4 million for the quarter, or $0.58 per basic and diluted share.
Kiora ended March 31, 2026 with $13.9 million in cash and short-term investments and subsequently raised an additional $5.0 million through a strategic equity financing. Management believes this supports an operational runway into late 2028, beyond anticipated data readouts from its KIO-301 ABACUS-2 and KIO-104 KLARITY Phase 2 trials.
Enrollment in ABACUS-2 for KIO-301 is roughly half complete, supported by strong patient demand and expanded trial sites, and prior ABACUS-1 data were published in Nature Medicine. KIO-104 continues in the KLARITY study, with a planned safety review expected to enable escalation to a higher dose cohort.
Kiora Pharmaceuticals, Inc. reported a net loss of $2.4 million for the three months ended March 31, 2026, compared with $2.2 million a year earlier, as it continues investing in ophthalmic drug development.
Total operating expenses were $2.5 million, including $1.6 million in general and administrative costs and $2.1 million in research and development, partly offset by $1.2 million of collaboration credits tied to the KIO‑301 program. Other income, mainly interest, added $0.1 million.
At March 31, 2026, Kiora held $11.0 million in cash and cash equivalents and $2.9 million in short‑term investments, with total assets of $21.2 million and stockholders’ equity of $13.9 million. Management states that, including $5 million raised in an April 2026 private placement and reimbursement of all KIO‑301 expenses by partner Théa Open Innovation, current resources are expected to fund planned operations into late 2028.
Kiora Pharmaceuticals, Inc. reported a net loss of $2.4 million for the three months ended March 31, 2026, compared with $2.2 million a year earlier, as it continues investing in ophthalmic drug development.
Total operating expenses were $2.5 million, including $1.6 million in general and administrative costs and $2.1 million in research and development, partly offset by $1.2 million of collaboration credits tied to the KIO‑301 program. Other income, mainly interest, added $0.1 million.
At March 31, 2026, Kiora held $11.0 million in cash and cash equivalents and $2.9 million in short‑term investments, with total assets of $21.2 million and stockholders’ equity of $13.9 million. Management states that, including $5 million raised in an April 2026 private placement and reimbursement of all KIO‑301 expenses by partner Théa Open Innovation, current resources are expected to fund planned operations into late 2028.
Kiora Pharmaceuticals is asking stockholders to vote at its 2026 annual meeting on director elections, executive pay, auditor ratification, and an equity plan increase. Three Class II directors are nominated to serve until 2029. Investors will cast a non-binding advisory vote on 2025 compensation for the CEO and other named executives, and on retaining Haskell & White LLP as independent auditor for 2026. The company also seeks approval to amend its 2024 Equity Incentive Plan to add 1,500,000 shares for future equity awards. As of the April 16, 2026 record date, 4,432,440 common shares were outstanding, each with one vote.
Kiora Pharmaceuticals is asking stockholders to vote at its 2026 annual meeting on director elections, executive pay, auditor ratification, and an equity plan increase. Three Class II directors are nominated to serve until 2029. Investors will cast a non-binding advisory vote on 2025 compensation for the CEO and other named executives, and on retaining Haskell & White LLP as independent auditor for 2026. The company also seeks approval to amend its 2024 Equity Incentive Plan to add 1,500,000 shares for future equity awards. As of the April 16, 2026 record date, 4,432,440 common shares were outstanding, each with one vote.
Kiora Pharmaceuticals entered into a private placement with institutional investors Perceptive Advisors and ADAR1 Capital Management, raising $5.0 million upfront and providing up to an additional $19.0 million in potential warrant exercise proceeds. The deal includes 438,471 common shares, pre-funded warrants for 1,527,711 shares, and Tranche A-1 and A-2 warrants for up to 9,830,909 additional shares at an exercise price of $1.94 per share. Warrants are immediately exercisable and have milestone-based terms tied to strategic transactions and completion of Phase 3 trial enrollment. The securities were issued under Regulation D exemptions and will later be registered for resale under a planned registration statement.
Kiora Pharmaceuticals entered into a private placement with institutional investors Perceptive Advisors and ADAR1 Capital Management, raising $5.0 million upfront and providing up to an additional $19.0 million in potential warrant exercise proceeds. The deal includes 438,471 common shares, pre-funded warrants for 1,527,711 shares, and Tranche A-1 and A-2 warrants for up to 9,830,909 additional shares at an exercise price of $1.94 per share. Warrants are immediately exercisable and have milestone-based terms tied to strategic transactions and completion of Phase 3 trial enrollment. The securities were issued under Regulation D exemptions and will later be registered for resale under a planned registration statement.
Kiora Pharmaceuticals CFO Melissa Tosca reported a routine tax-related share disposition. On April 1, 2026, 929 shares of Kiora Pharmaceuticals common stock were delivered at $1.95 per share to pay an exercise price or tax liability. After this tax-withholding disposition, Tosca directly holds 26,975 shares of common stock, indicating the transaction affected only a small portion of her position and was not an open-market sale.
Kiora Pharmaceuticals CFO Melissa Tosca reported a routine tax-related share disposition. On April 1, 2026, 929 shares of Kiora Pharmaceuticals common stock were delivered at $1.95 per share to pay an exercise price or tax liability. After this tax-withholding disposition, Tosca directly holds 26,975 shares of common stock, indicating the transaction affected only a small portion of her position and was not an open-market sale.
Kiora Pharmaceuticals Chief Development Officer Eric Joseph Daniels reported a tax-related share disposition. On the transaction date, 929 shares of Kiora Pharmaceuticals common stock were withheld at $1.95 per share to cover tax obligations. After this non-open-market tax-withholding disposition, Daniels directly held 31,741 shares of common stock.
Kiora Pharmaceuticals Chief Development Officer Eric Joseph Daniels reported a tax-related share disposition. On the transaction date, 929 shares of Kiora Pharmaceuticals common stock were withheld at $1.95 per share to cover tax obligations. After this non-open-market tax-withholding disposition, Daniels directly held 31,741 shares of common stock.